home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

RUURD STOLP, D.V.M., Ph.D.
Senior Vice President and President, Global Animal Health
Schering-Plough Corporation
Boxmeer, The Netherlands

Ruurd Stolp, D.V.M., Ph.D., is senior vice president and president, Global Animal Health, for Schering-Plough Corporation.

Stolp was named to his position at Schering-Plough in November 2007. He is responsible for overseeing the company's worldwide animal health business, which includes a range of pharmaceuticals, vaccines, growth promotants, anti-infectives and anti-parasiticides for food-producing and companion animals.

Previously, Stolp was president of Intervet International, a position he held since 2002. From 1996 to 2002, he was responsible for the global manufacturing organization. Also while at Intervet, Stolp was based in the U.S. for a time, during which he was vice president, Technical Affairs. Before joining Intervet in 1987, Stolp worked during 4 years at a veterinary hospital in the Netherlands.

Stolp graduated from the University of Utrecht in 1980 with a veterinary degree. He specialized in Companion Animal Internal Medicine and completed his Ph.D. degree in 1985 at the Faculty of Veterinary Medicine, also at Utrecht University.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

 

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough